// App-Quantinova.ai

TPS508 : Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.

Researchers

Presenter

  • Andrew James Weickhardt

Principal Investigators

  • Michiel Simon Van Der Heijden

  • Arjun Vasant Balar

  • Shahrokh F. Shariat

  • Neal D. Shore

  • Xiao Fang

  • James Luke Godwin

  • Ekta Kapadia

  • Jeff M. Michalski

  • Nicholas D. James

Medical Centers

  • Olivia Newton-John Cancer and Wellness Centre, Melbourne, Australia

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Perlmutter Cancer Center NYU Langone, New York, NY

  • Medical University of Vienna, Vienna, Austria

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Merck & Co., Inc., Kenilworth, NJ

  • Washington University in St. Louis, Department of Radiation Oncology, St. Louis, MO

  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom

Locations

  • Australia

  • Netherlands

  • United States

  • Austria

  • United Kingdom

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Adrucil injection

  • Pembrolizumab

  • Fluorouracil

  • Gemcitabine

  • mitomycin

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02662062

  • NCT02621151

  • NCT04241185

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved